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Abstract
Introduction: Although substitutions of antiretroviral regimen are generally safe, most data on substitutions are based on
results from clinical trials. The objective of this study was to evaluate the treatment outcomes of substituting antiretroviral
regimen in virologically suppressed HIV-infected patients in non-clinical trial settings in Asian countries.
Methods: The study population consisted of HIV-infected patients enrolled in the TREAT Asia HIV Observational Database
(TAHOD). Individuals were included in this analysis if they started combination antiretroviral treatment (cART) after 2002,
were being treated at a centre that documented a median rate of viral load monitoring ≥0.8 tests/patient/year among TAHOD
enrolees, and experienced a minor or major treatment substitution while on virally suppressive cART. The primary endpoint to
evaluate outcomes was clinical or virological failure (VF), followed by an ART class change. Clinical failure was defined as death
or an AIDS diagnosis. VF was defined as confirmed viral load measurements ≥400 copies/mL followed by an ART class change
within six months. Minor regimen substitutions were defined as within-class changes and major regimen substitutions were
defined as changes to a drug class. The patterns of substitutions and rate of clinical or VF after substitutions were analyzed.
Results: Of 3994 adults who started ART after 2002, 3119 (78.1%) had at least one period of virological suppression. Among
these, 1170 (37.5%) underwent a minor regimen substitution, and 296 (9.5%) underwent a major regimen substitution during
suppression. The rates of clinical or VF were 1.48/100 person years (95% CI 1.14 to 1.91) in the minor substitution group,
2.85/100 person years (95% CI 1.88 to 4.33) in the major substitution group and 2.53/100 person years (95% CI 2.20 to
2.92) among patients that did not undergo a treatment substitution.
Conclusions: The rate of clinical or VF was low in both major and minor substitution groups, showing that regimen substitu-
tion is generally effective in non-clinical trial settings in Asian countries.
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1 | INTRODUCTION
Combination antiretroviral treatments (cART) have been
widely available in Asia since 2003 [1]. However, most Asian
HIV clinics have limited resources and are able to prescribe
regimens based on WHO global treatment guidelines, which
recommend dual nucleoside reverse transcriptase inhibitors
(NRTIs) plus a non-nucleoside reverse transcriptase inhibitor
(NNRTI) for first-line therapy [1]. Current WHO guidelines
recommend use of a ritonavir-boosted protease inhibitor (PI)
in combination with dual NRTIs after failure on a first line
NNRTI-based regimen, which is widely practiced in Asia [2]. A
prior TREAT Asia HIV Observational Database (TAHOD)
study reported that among 302 patients with first-line treat-
ment failure, 73% switched to a dual NRTI plus boosted PI
regimen [3]. Use of ritonavir-boosted lopinavir (LPV/r) or ata-
zanavir (ATV/r) compromised the majority of boosted PI use
beyond 2006 in this cohort [3]. Most commonly used NRTIs
for second-line treatment were lamivudine/emtricitabine
(3TC/FTC), tenofovir (TDF) and zidovudine (AZT), accounting
for 76.5%, 44.4% and 32.1% of all patients respectively [3].
Prior to 2003, PI-based ART was more commonly used in
small numbers of patients [1]. The availability of generic nevi-
rapine (NVP) and efavirenz (EFV) allowed expansion of cART
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due to supply and cost [4]. In a cohort study of 4662 patients
treated in Asia, stavudine (d4T) plus another NRTI plus
NNRTI was the most common first-line regimen used from
2003 to 2006 [1]. However, between 2003 and 2013 first
line d4T use decreased from 68.2% to 5.8% in the cohort, fre-
quently because of side effects such as lipodystrophy and
peripheral neuropathy [1]. Currently, the region is phasing out
d4T use according to the WHO 2010 recommendations [5].
More recently, integrase inhibitors (INSTIs) including dolute-
gravir (DTG) and elvitegravir (EVG) have begun to be intro-
duced [6].
Despite great advances in antiretroviral therapy in the last
decade, several limitations remain including adverse effects,
suboptimal adherence, tolerability problems and drug–drug
interactions [7–9]. Substitution of cART in stable, virologically
suppressed patients with the aim of improving tolerability and
convenience is a common practice in clinical settings [10].
Data on the safety and durability of virological suppression
following switches within or across antiretroviral classes have
largely come from randomized controlled trials. For example
the SPIRAL study demonstrated non-inferior efficacy in
switching from ritonavir-boosted PI to raltegravir (RAL) [11],
the EASIER ANRS 138 trial demonstrated that switch from
enfuvirtide to RAL in well-suppressed patients with multidrug-
resistant HIV infection was generally well tolerated and had
sustained efficacy [12], and the STRATEGY-NNRTI trial
demonstrated non-inferiority in switching to co-formulated
elvitegravir-cobicistat-emtricitabine-tenofovir (ECF/TDF) ver-
sus continuation NNRTI with FTC and TDF [13].
However, data on the outcomes of these switches from
real-world clinic data have been lacking. Therefore, the objec-
tive of this study was to evaluate the treatment outcomes of
substituting antiretroviral regimen in virologically suppressed
HIV-infected patients in non-clinical trial settings in Asian
countries.
2 | METHODS
2.1 | Patient selection
The study population consisted of HIV-infected patients
enrolled in the TAHOD before March 30, 2016. This cohort
contributes to the International Epidemiology Databases to
Evaluate AIDS (IeDEA) global consortium and has been
described previously [14–16]. Recruitment started in 2003. In
March 2016, TAHOD included data from 8928 adults
(≥18 years of age) that had ever received care from one of
20 clinics in 12 Asian countries. These sites are predominantly
public or university-based HIV referral clinics. Ethics approval
is obtained at the sites, TREAT Asia/amfAR (coordinating cen-
tre), and the Kirby Institute (data management and statistical
analysis centre). Patient consent was deferred according to
the individual participating sites and their institutional review
boards, and is not required for all participants. Individuals
were included in this analysis if they started cART after 2002,
were being treated at a centre that documented a median
rate of viral load monitoring ≥0.8 tests/patient/year among
TAHOD enrolees, and experienced a minor or major treat-
ment switch while on virally suppressive ART. Among the 20
cohort sites, only data from the 12 sites which performed VL
test rate >0.8 in every year were included in this analysis:
Table 1. Baseline characteristics at minor and major regimen
switch
Characteristic
Minor switch
group N = 1170
Major switch
group N = 296
Age (years)
Median (IQR) 41.8 (36.0
to 48.0)
42.7 (35.8
to 50.3)
Sex
Male 782 66.8% 250 84.5%
HIV exposure
Heterosexual 788 67.4% 109 36.8%
Homosexual 294 25.1% 157 53.0%
IDU 20 1.7% 2 0.7%
Other 68 5.8% 28 9.5%
Hepatitis B surface antigen status
Negative, % tested 979 90.1% 243 91.7%
Positive, % tested 108 9.9% 22 8.3%
Unknown 83 7.1% 31 10.5%
Hepatitis C antibody status
Negative, % tested 961 93.2% 255 95.5%
Positive, % tested 70 6.8% 12 4.5%
Unknown 139 11.9% 29 9.8%
Prior AIDS diagnosis
Yes 525 44.9% 102 34.5%
Using cotrimoxazole prophylaxis
Yes 114 9.7% 19 6.4%
CD4 cell count (cells/mm3)
Median (IQR) 432 (300 to
589)
490 (338 to
643)
Number tested 1019 87.1% 271 91.6%
Nadir CD4 cell count (cells/mm3)
Median (IQR) 107 (33 to 209) 170 (77 to 271)
Number tested 1170 100.0% 295 99.7%
Peak HIV viral load (copies/mL)
Median (IQR) 101,500 (37,800 to
365,000)
100,501 (32,225 to
313,500)
Number tested 822 70.3% 236 79.7%
Time on ART (years)
Median (IQR) 3.2 (1.8 to 4.9) 3.5 (2.1 to 6.9)
Duration of suppression (years)
Median (IQR) 1.8 (0.7 to 3.4) 2.8 (1.3 to 6.2)
Adverse event-associated switch
Yes 618 52.8% 158 53.4%
Period of treatment switch
2003 to 2006 142 12.1% 13 4.4%
2007 to 2009 238 20.3% 41 13.9%
2010 to 2012 482 41.2% 105 35.5%
2013 to 2016 308 26.3% 137 46.3%
Country income status
High 374 32.4% 218 74.4%
Middle/low 780 67.6% 75 25.6%
Values are n (% total) unless otherwise indicated. ART, antiretroviral
therapy.
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Hong Kong (n = 1), India (n = 1), Japan (n = 1), Malaysia
(n = 2), Singapore (n = 1), South Korea (n = 1), Taiwan (n = 1)
and Thailand (n = 4).
2.2 | Baseline data and outcome definitions
Two analyses were conducted to evaluate minor and major
treatment substitutions separately. Viral suppression was
defined as having had two viral load measurements
<400 copies/mL between 90 to 390 days apart. Periods of
viral suppression were considered to begin from the date of
the second viral load <400 copies/mL. Minor regimen substi-
tutions were defined as within-class changes (e.g. d4T to TDF,
EFV to NVP) and major regimen substitutions were defined as
changes to a drug class (e.g. NNRTI to PI, PI to INSTI). Base-
line time in both analyses (minor switches and major switches)
was defined as the date of first ART substitution after achiev-
ing viral suppression. Patients who had never received mono/
dual therapy prior to baseline were excluded. For an approxi-
mate reference point, we also evaluated rates of VF among
patients who never underwent an ART switch. The baseline
date used to calculate follow-up time for the non-switch group
was the date of viral suppression. The primary endpoint to
evaluate outcomes was clinical or virological failure (VF), fol-
lowed by an ART class change. Clinical failure was defined as
death or an AIDS diagnosis. VF was defined as confirmed viral
load measurements ≥400 copies/mL followed by an ART class
change within six months [17,18].
The reason for treatment substitution was categorized as
adverse event (AE)-associated when a patient had any docu-
mentation of an adverse event-associated treatment substitu-
tion (as determined by the treating physician) between the date
of viral suppression and baseline. Patients were considered hep-
atitis B (HBV) co-infected if they had any record of a positive
HBV surface antigen test, and hepatitis C (HCV) co-infected if
they had any record of a positive HCV antibody test. The win-
dow period for baseline CD4 cell count testing was between
three months before baseline to three months after baseline.
Where multiple test results were available within this period,
the measurement closest to the time of treatment substitution
was used. Nadir CD4 cell count was defined as the lowest docu-
mented CD4 cell count prior to baseline. Peak HIV-1 RNA level
(viral load, VL) was defined as the highest documented VL prior
to baseline. Country income status was defined according to
World Bank categorizations [19]. Loss to follow-up was defined
as not having been seen at clinic for >6 months without docu-
mentation of clinic transfer.
2.3 | Statistical analysis
The rates of virological failure after treatment substitutions
were calculated. Competing risk regression was used to deter-
mine factors associated with VF after treatment substitution.
Loss to follow up and major treatment substitution after base-
line were considered competing risks. Type of treatment sub-
stitution, reason for treatment substitution (adverse event or
other), baseline age, sex, HIV exposure category, HBV surface
antigen/HCV antibody positivity, AIDS diagnosis prior to base-
line, nadir CD4 count, peak viral load, period of treatment
substitution and country income status were evaluated as
fixed covariates. Co-trimoxazole use, CD4 cell count and ART
adherence were evaluated as time-updated covariates. The
final models included type of ART substitution, baseline age,
sex, CD4 cell count, ART adherence, period of treatment sub-
stitution and country income status. Any other variables found
to be significant after adjusting for these core variables were
also included. Patients with missing data were included in all
analyses but hazard ratios for missing categories are not
reported. Stata (StataCorp, College Station, TX) version 14.1
was used for all statistical analysis.
3 | RESULTS
Of the 3994 adults who started ART after 2002, 3119
(78.1%) had at least one period of virological suppression.
Table 2. Minor and Major regimen switch characteristics
Switch class
description
Number of
switches
Median (IQR) CD4 cell count at
switch (cells/mm3), number
with measurement
Median (IQR) duration of HIV
suppression at switch (years)
Number of switches
associated with AE (% within
switch category)
Minor
NRTI only 825 436 (303 to 593), n = 709 1.8 (0.7 to 3.5) 446 (54.1)
NNRTI only 70 430 (272 to 605), n = 63 1.8 (0.7 to 3.5) 39 (55.7)
PI only 101 443 (291 to 579), n = 89 1.8 (0.6 to 2.9) 50 (49.5)
INSTI only 3 485 (474 to 504), n = 3 0.5 (0.3 to 2.8) 1 (33.3)
Multiple within
class switches
171 388 (292 to 579), n = 155 1.8 (0.7 to 3.6) 82 (48.0)
Major
NRTI only 78 397 (249 to 547), n = 71 1.7 (0.7 to 3.5) 45 (57.7)
NNRTI only 88 514 (382 to 632), n = 80 3.2 (1.5 to 6.9) 36 (40.9)
PI only 95 580 (426 to 687), n = 89 4.3 (2.0 to 7.2) 64 (67.4)
Other 35 365 (272 to 574), n = 31 2.2 (1.2 to 5.2) 13 (37.1)
NRTI, nucleoside reverse transcriptase inhibitors; NNRTI, non-nucleoside reverse transcriptase inhibitor; PI, protease inhibitor; INSTI, integrase
inhibitors; AE, adverse events.
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Table 3. Crude risk and hazard ratios for virological failure with different patterns of minor ART switch
Covariate VF
Patient years
follow up
Rate per 100
patient/years
(95% CI)
Univariate HR
(95% CI) p
Multivariate
HR (95% CI) p
Type of minor ART switcha
NRTI only 43 2885.8 1.49 (1.11 to 2.01) 1.00 1.00
NNRTI only 2 176.5 1.13 (0.28 to 4.53) 0.65 (0.16 to 2.67) 0.55 0.55 (0.13 to 2.35) 0.42
PI only 7 376.5 1.86 (0.89 to 3.90) 1.38 (0.62 to 3.03) 0.43 1.40 (0.57 to 3.42) 0.46
INSTI only or multiple within class switches 7 558.3 1.25 (0.60 to 2.63) 0.78 (0.35 to 1.74) 0.55 0.63 (0.28 to 1.40) 0.26
AE associated switch
No 30 1877.0 1.60 (1.12 to 2.29) 1.00
Yes 29 2120.2 1.37 (0.95 to 1.97) 0.87 (0.52 to 1.44) 0.59
Baseline agea
Per 5 years older 59 3997.2 1.48 (1.14 to 1.91) 1.10 (0.98 to 1.23) 0.12 1.09 (0.96 to 1.23) 0.19
Sexa
Male 47 2670.0 1.76 (1.32 to 2.34) 1.00 1.00
Female 12 1327.2 0.90 (0.51 to 1.59) 0.50 (0.26 to 0.95) 0.03 0.66 (0.35 to 1.27) 0.21
HIV exposure
Heterosexual 37 2641.8 1.40 (1.01 to 1.93) 1.00
Homosexual 16 1052.9 1.52 (0.93 to 2.48) 1.20 (0.67 to 2.14) 0.55
IDU/other 6 302.5 1.98 (0.89 to 4.42) 1.38 (0.58 to 3.28) 0.46
Hepatitis B surface antigen status
Negative 52 3304.1 1.57 (1.20 to 2.07) 1.00
Positive 5 402.8 1.24 (0.52 to 2.98) 0.84 (0.33 to 2.12) 0.71
Unknown 2 290.3 0.69 (0.17 to 2.75) –
Hepatitis C antibody status
Negative 50 3312.9 1.51 (1.14 to 1.99) 1.00
Positive 6 211.6 2.84 (1.27 to 6.31) 1.64 (0.71 to 3.83) 0.25
Unknown 3 472.8 0.63 (0.20 to 1.97) –
Prior AIDS diagnosis
No 31 2145.7 1.44 (1.02 to 2.05) 1.00
Yes 28 1851.5 1.51 (1.04 to 2.19) 1.09 (0.65 to 1.81) 0.74
Current cotrimoxazole use
No 56 3765.5 1.49 (1.14 to 1.93) 1.00
Yes 3 231.7 1.29 (0.42 to 4.01) 0.73 (0.23 to 2.33) 0.59
Current CD4 cell count (cells/mm3)a
>500 17 1832.3 0.93 (0.58 to 1.49) 1.00 1.00
350 to 500 17 1122.3 1.51 (0.94 to 2.44) 1.48 (0.75 to 2.92) 0.25 1.39 (0.68 to 2.83) 0.37
<350 21 926.7 2.27 (1.48 to 3.48) 1.93 (1.01 to 3.70) 0.05 1.59 (0.79 to 3.21) 0.19
Unknown 4 115.8 3.45 (1.30 to 9.20) – –
Nadir CD4 cell count (cells/mm3)
>350 3 236.2 1.27 (0.41 to 3.94) 1.00
200 to 350 12 928.5 1.29 (0.73 to 2.28) 0.91 (0.26 to 3.19) 0.88
<200 44 2832.5 1.55 (1.16 to 2.09) 1.02 (0.32 to 3.26) 0.97
Peak HIV viral load (copies/mL)
<100,000 16 1162.1 1.38 (0.84 to 2.25) 1.00
≥100,000 25 1383.5 1.81 (1.22 to 2.67) 1.22 (0.65 to 2.28) 0.54
Unknown 18 1451.5 1.24 (0.78 to 1.97) –
Current ART adherencea
100% 27 3491.3 0.77 (0.53 to 1.13) 1.00 1.00
<100% 4 172.2 2.32 (0.87 to 6.19) 3.01 (1.05 to 8.61) 0.04 2.79 (0.92 to 8.45) 0.07
Unknown 28 333.7 8.39 (5.79 to 12.15) – –
Period of treatment switcha
2003 to 2006 13 633.2 2.05 (1.19 to 3.54) 1.00 1.00
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Among these, 296 (9.5%) underwent a major regimen substi-
tution during suppression, and 1170 (37.5%) underwent a
minor regimen substitution during suppression. A total of 17
patients in the minor switch, six in the major switch and 69 in
the non-switch group were confirmed with two consecutive
viral load measurements ≥400 copies/mL. Patients confirmed
with a single viral load ≥400 copies/mL were 13, 3 and 28 in
the minor, major and non-switch group respectively. AIDS
diagnosis was confirmed in 14, 7 and 65 patients in the minor,
major and non-switch group respectively. Death was con-
firmed in 15, 6 and 31 patients in the minor, major and non-
switch group respectively.
The baseline characteristics of the study participants are
described in Table 1. In the minor and major switch groups,
the median (IQR) age of the patients were 41.8 (36 to 48),
and 42.7 (35.8 to 50.3) years respectively. Seven hundred and
eighty-two (66.8%) were male in the minor switch group, and
250 (84.5%) in the major switch group. Heterosexual trans-
mission accounted for 788 (67.4%), and 109 (36.8%) in the
minor and major switch groups. Homosexual transmission
accounted for 294 (25.1%), and 157 (53.0%) in each groups.
The CD4 cell count was 432 (300 to 589) cells/mm3 in the
minor switch group, and 490 cells/mm3 (338 to 643) in the
major switch group. 618 (52.8%) and 158 (53.4%) switches
were associated with an adverse events in the minor and
major switch groups respectively.
Table 2 describes the switch characteristics in each group.
In the minor substitution group, 825 patients switched
between NRTI only, 70 patients switched between NNRTI
only, 101 patients switched between PI only, three patients
switched between INSTI only and 171 patients experienced
multiple within class substitutions. In the major substitution
group, 78 patients switched from NNRTI to PI, 88 patients
switched from PI to NNRTI, 95 patients switched from PI to
INSTI and 35 patients experienced other regimen switch.
The number of patients in the minor switch group who
switched due to adverse events was 446 in the NRTI only
group, 39 in the NNRTI only group, 50 in the PI only group,
1 in the INSTI only group and 82 in patients who had multi-
ple within class switches. The number of patients who experi-
enced major switch due to adverse events was 45 in the
NNRTI to PI group, 36 in the PI to NNRTI group, 64 in the
PI to INSTI group and 13 in the other regimen substitution
group.
The rates of VF were 2.85 per 100 person years (95% CI
1.88 to 4.33) in the major substitution group and 1.48 per
100 person years (95% CI 1.14 to 1.91) in the minor substitu-
tion group. The rate of VF among patients that did not
undergo any treatment substitution during suppression
(n = 1756) was 2.53 per 100 person years (95% CI 2.20 to
2.92). The median (IQR) duration of follow-up was 3.1 (1.3 to
5.1) years in the minor switch analysis and 1.8 (0.9 to 3.7)
years in the major switch analysis. Rates of loss to follow up
were 1.7 per 100 patient years (95% CI 1.3 to 2.1) and 1.7
per 100 patient years (95% CI 1.0 to 2.9) respectively.
Tables 3 and 4 demonstrate the crude risk and hazard ratios
for VF with different patterns of minor and major switch. The
results in both groups were similar, showing both groups of
switching were not a significant risk factor for VF.
4 | DISCUSSION
The objective of this study was to analyse, in real-world set-
tings, the rate of VF when substituting ART in virologically
suppressed HIV-infected patients. In our study, the rate of VF
during virological suppression was low in patients who had
undergone both minor and major ART switches. These results
are consistent with prior studies that ART substitution in viro-
logically suppressed HIV-infected patients is generally effec-
tive [20,21].
Prior studies in clinical trials have proven that switching
EFV, for intolerance or toxicity, to NVP or rilpivirine (RPV) is
generally safe and efficacious [22,23]. In the open-label, phase
3b SPIRIT trial concerning 476 patients with no history of VF,
switching from a PI-based regimen to RPV with FTC and TDF
proved to be non-inferior [24]. The STRATEGY-NNRTI trial
demonstrated non-inferiority of ECF/TDF vs. continuation
NNRTI with FTC and TDF [13], and the STRATEGY-PI trial
also demonstrated non-inferiority of simplification to ECF/TDF
vs. continuation of ritonavir-boosted PI with FTC/TCF in viro-
logically suppressed adults [25]. In both treatment groups cre-
atinine concentrations increased non-progressively in patients
who switched regimens, as expected because of inhibition of
Table 3. (Continued)
Covariate VF
Patient years
follow up
Rate per 100
patient/years
(95% CI)
Univariate HR
(95% CI) p
Multivariate
HR (95% CI) p
2007 to 2009 11 1131.7 0.97 (0.54 to 1.76) 0.49 (0.22 to 1.08) 0.08 0.87 (0.38 to 1.97) 0.73
2010 to 2012 26 1775.6 1.46 (1.00 to 2.15) 0.61 (0.31 to 1.18) 0.14 1.44 (0.71 to 2.94) 0.31
2013 to 2016 9 456.7 1.97 (1.03 to 3.79) 0.60 (0.25 to 1.46) 0.26 1.41 (0.54 to 3.69) 0.48
Country income statusa
High 25 1310.0 1.91 (1.29 to 2.82) 1.00 1.00
Middle/low 34 2615.0 1.30 (0.93 to 1.82) 0.61 (0.36 to 1.02) 0.06 0.85 (0.46 to 1.59) 0.62
Patient with missing data were included in all analyses, however, HRs for unknown categories are not shown. ART, antiretroviral therapy; VF, viro-
logical failure; HR, hazard ratio; NRTI, nucleoside reverse transcriptase inhibitors; NNRTI, non-nucleoside reverse transcriptase inhibitor; PI, pro-
tease inhibitor; INSTI, integrase inhibitors; AE, adverse events.
aIncluded in final model.
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Table 4. Crude risk and hazard ratios for virological failure with different patterns of major ART switch
Covariate VF
Patient years
follow up
Rate per 100pt/yrs
(95% CI)
Univariate HR
(95% CI) p
Multivariate
HR (95% CI) p
Type of major ART switcha
NNRTI to PI 12 245.6 4.89 (2.78 to 8.60) 1.00 1.00
PI to NNRTI 1 284.2 0.35 (0.05 to 2.50) 0.08 (0.01 to 0.61) 0.02 0.13 (0.01 to 1.43) 0.10
PI to INSTI 5 167.4 2.99 (1.24 to 7.18) 0.44 (0.16 to 1.27) 0.13 0.45 (0.11 to 1.75) 0.25
Other 4 74.9 5.34 (2.01 to 14.24) 0.87 (0.28 to 2.68) 0.81 1.05 (0.30 to 3.73) 0.94
AE-associated switch
No 9 354.7 2.54 (1.32 to 4.88) 1.00
Yes 13 417.4 3.11 (1.81 to 5.36) 1.23 (0.52 to 2.88) 0.64
Baseline agea
Per 5 years older 22 772.0 2.85 (1.88 to 4.33) 1.17 (0.93 to 1.47) 0.19 1.08 (0.85 to 1.38) 0.51
Sexa
Male 20 632.3 3.16 (2.04 to 4.90) 1.00 1.00
Female 2 139.7 1.43 (0.36 to 5.72) 0.47 (0.11 to 2.09) 0.32 0.42 (0.07 to 2.65) 0.36
HIV exposure
Heterosexual 8 324.2 2.47 (1.23 to 4.93) 1.00
Homosexual 12 372.6 3.22 (1.83 to 5.67) 1.19 (0.48 to 2.94) 0.70
IDU/other 2 75.2 2.66 (0.67 to 10.64) 0.97 (0.20 to 4.64) 0.97
Hepatitis B surface antigen status
Negative 16 622.6 2.57 (1.57 to 4.20) 1.00
Positive 3 55.2 5.43 (1.75 to 16.84) 2.03 (0.63 to 6.56) 0.24
Unknown 3 94.2 3.18 (1.03 to 9.87) –
Hepatitis C antibody status
Negative 19 652.5 2.91 (1.86 to 4.57) 1.00
Positive 1 34.9 2.86 (0.40 to 20.33) 1.11 (0.14 to 8.89) 0.92
Unknown 2 84.7 2.36 (0.59 to 9.45) –
Prior AIDS diagnosisa
No 10 497.9 2.01 (1.08 to 3.73) 1.00 1.00
Yes 12 274.1 4.38 (2.49 to 7.71) 2.30 (1.00 to 5.26) 0.05 2.37 (1.01 to 5.58) 0.05
Current cotrimoxazole use
No 21 736.0 2.85 (1.86 to 4.38) 1.00
Yes 1 36.1 2.77 (0.39 to 19.67) 0.71 (0.09 to 5.59) 0.75
Current CD4 cell count (cells/mm3)a
>500 8 433.4 1.85 (0.92 to 3.69) 1.00 1.00
350 to 500 5 188.9 2.65 (1.10 to 6.36) 1.23 (0.41 to 3.75) 0.71 0.96 (0.29 to 3.20) 0.94
<350 7 124.0 5.64 (2.69 to 11.84) 2.02 (0.74 to 5.49) 0.17 1.01 (0.30 to 3.44) 0.98
Unknown 2 25.8 7.76 (1.94 to 31.02) – –
Nadir CD4 cell count (cells/mm3)
≥200 8 357.0 2.24 (1.12 to 4.48) 1.00
<200b 14 415.0 3.37 (2.00 to 5.70) 1.32 (0.55 to 3.16) 0.53
Peak HIV viral load (copies/mL)
<100,000 6 327.8 1.83 (0.82 to 4.07) 1.00
≥100,000 10 285.2 3.51 (1.89 to 6.52) 1.62 (0.58 to 4.53) 0.36
Unknown 6 159.1 3.77 (1.69 to 8.39) –
Current ART adherencea
100% 12 621.7 1.93 (1.10 to 3.40) 1.00 1.00
<100% 1 55.9 1.79 (0.25 to 12.69) 0.76 (0.10 to 5.84) 0.79 0.70 (0.09 to 5.63) 0.74
Unknown 9 94.4 9.53 (4.96 to 18.32) – –
Period of treatment switcha
2003 to 2009 6 294.2 2.04 (0.92 to 4.54) 1.00 1.00
2010 to 2012 13 299.5 4.34 (2.52 to 7.47) 1.42 (0.57 to 3.56) 0.45 1.21 (0.43 to 3.39) 0.72
2013 to 2016 3 178.3 1.68 (0.54 to 5.22) 0.39 (0.10 to 1.51) 0.17 0.43 (0.10 to 1.82) 0.25
Jung IY et al. Journal of the International AIDS Society 2017, 20:e25016
http://onlinelibrary.wiley.com/doi/10.1002/jia2.25016/full | https://doi.org/10.1002/jia2.25016
6
creatinine secretion by cobicistat [26]. Treatment discontinua-
tion because of adverse events was rare across both trials
[26]. The results of our study in non-clinical trial settings in
Asian countries support these findings, with a low frequency
of VF and adverse events in patients who experienced minor
or major substitution.
Although the rate of VF were generally low in both major and
minor substitution groups, patients who had a history of prior
AIDS diagnosis in our major substitution analysis had a slightly
higher risk of VF compared to those without a history of AIDS
(2.37; 95% CI 1.01 to 5.58, p = 0.05). In one study with 3447
HIV-infected patients, protective factors for VF were older age,
higher CD4 cell count and medication adherence [27]. In
another study by Grabar et al. considering patients receiving PI-
based therapy, low baseline CD4 cell count and high viral load
were both independent predictors of both virological and clini-
cal failure. Neither the type of PI or previous ART taken was
associated with risk of clinical progression [28]. In our study,
neither low nadir CD4 count nor high viral load was associated
with increased risk of VF. However, there were only 44 and 14
patients with nadir CD4 cell counts lower than 200 cells/mm3
in the minor and major substitution group respectively. The rea-
son for the difference in results may be explained by the smaller
number of patients in this study compared to the Grabar et al.
study, which included 975 patients.
There are several limitations to this study. First, TAHOD par-
ticipating sites are generally urban referral centres, and each
site recruits patients who are considered by local clinicians to
have a reasonably good prospect of long-term follow-up. This
limits the generalizeability of the results, as viral suppression
may have been overestimated relative to the background popu-
lation. Second, the number of patients, especially those patients
with major substitutions limited the statistical power of this
study. Third, the reasons for changing regimens for each individ-
ual were not clearly identifiable from our observational data-
base; thus, we could not draw inferences about whether certain
ART switch situations were riskier than others. Finally, patients
that did not switch do not have a comparable baseline date as
they do not have a date of ART switch. The difference in base-
line makes comparison between the three groups difficult.
In a real-world multisite Asian cohort of cohorts, we found
rates of clinical or VF to be low in patients who had under-
gone both minor and major switches in ART medications. This
supports the finding that ART regimen substitution in virologi-
cally suppressed patients is effective in non-clinical trial set-
tings in Asian countries.
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